Short answer
Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on November 12, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Investor presentation furnished as Exhibit 99.1 for use in investor meetings.
Oncology Institute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Investor presentation furnished as Exhibit 99.1 for use in investor meetings
- Presentation may contain material updates on Starling Oncology’s strategy, pipeline, or outlook requiring review before investment decisions
Item EX-99.1 · Exhibit EX-99.1
- Investor presentation outlines oncology value-based care model across capitation, fee-for-service, specialty pharmacy, and clinical services
- FY2026 revenue guidance $650–660M, adjusted EBITDA $4–6M, and free cash flow $5–10M
- 3Q26 revenue $169.8M, up 24% YoY, with adjusted EBITDA $3.4M versus $(3.5)M in 3Q25
- Specialty pharmacy revenue $109M, up 44% YoY, with 24% gross margin
- MLR 81%, down 400 basis points sequentially, while delegated contracts ramp and remain a key margin risk
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oncology Institute, Inc. 8-K filings
Get the next TOI 8-K as it lands
Follow TOI for push alerts, or ask the research agent what this filing means.